~~<i id='EDFB031C5C'><strike id='EDFB031C5C'><tt id='EDFB031C5C'><pre id='EDFB031C5C'></pre></tt></strike></i>~~

Home» Wikipedia» hotspot

hotspot

author：focus 2025-10-02 12:15:49 Page View：3568

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Zyn nicotine pouches become unlikely player in latest culture war
Next article： Cancer drug shortages should be causing more outrage

explore

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

The Affordable Care Act has saved billions in health care costs

PresidentObamasignstheAffordableCareActintheEastRoomoftheWhiteHouseonMarch23,2010.AlexWong/GettyImag

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

AdobeAcadiaPharmaceuticalssaidMondaythatitsapprovedmedicinecalledNuplazidfailedtoimprovethesocialand